Food and Drug Administration (FDA) has cleared the Pfizer coronavirus (COVID-19) vaccine for use on children under 16.
On Monday, May 10, the FDA extended the emergency use authorization given to the Pfizer-BioNTech COVID-19 vaccine to allow for the vaccination of kids between 12 and 15. This decision will allow middle school students to get vaccinated before the fall.
The emergency use authorization was granted after studies released by Pfizer claiming that the pharma company’s coronavirus vaccine was 100 percent effective in adolescents.
Pfizer’s trial involved 2,260 adolescents between the ages of 12 and 15, with around an even number of people getting the Pfizer vaccine and the placebo. According to the company, there were 18 cases of COVID-19 in the placebo group and zero in the vaccine group, resulting in a 100 percent efficacy in preventing illness. (Related: Two-year-old baby DIES during Pfizer’s COVID-19 vaccine experiments on children.)
Share This
The FINANCIAL Recent news reports proclaiming pediatric mental health visits to the ER are on the rise, youth suicide is at a record high, and half of all college students meet the criteria for one or more mental health disorders are telling us that we have a problem on our hands. To explore the issues behind the headlines, Columbia’s Department of Psychiatry and School of Journalism recently hosted an online forum, “Youth and Mental Illness: What is Going On?”, the third in an ongoing series of mental health programs developed by the Columbia Department of Psychiatry and School of Journalism.
May 21, 2021
Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR.
On the whole, the early data suggest these devices are a viable treatment for tricuspid regurgitation (TR), investigators told the meeting’s virtual audience, yet they also speak to the diverse approaches annular reduction, transcatheter edge-to-edge repair (TEER), and valve replacement aimed at addressing this clinical niche.
All three are manufactured by Edwards Lifesciences:
Thirty-day data from TRISCEND make the case for valve replacement, specifically with the Evoque device, in patients with symptomatic and at least moderate TR.
10 Early Warning Signs of Dementia - Symptoms of Alzheimer s prevention.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prevention.com Daily Mail and Mail on Sunday newspapers.
May 19, 2021
Compared with second-generation DES, devices with ultrathin struts are associated with less TLF, driven by reductions in clinically driven TLR, a long-term meta-analysis of multiple RCTs suggests.
The thinner struts have been thought to offer advantages in terms of producing less inflammation, vessel injury, neointimal proliferation, and thrombus formation. The new meta-analysis builds on the findings of a prior meta-analysis showing that ultrathin-strut DES were associated with a lower risk of TLF (composite of cardiac death, MI, or clinically driven TLR) at 1 year compared with conventional second-generation thin-strut DES.
Several additional
large-scale RCTs that have been completed in recent years, with extended follow-up to a mean of 2.5 years, differentiate the newer meta-analysis, which was presented today by Yousif Ahmad, MD (Cedars-Sinai Medical Center, Los Angeles, CA), at the EuroPCR 2021 virtual meeting. It was also simultaneously published in the